{"id":"doi:10.4103/nrr.nrr-d-25-00759","kind":"review","title":"Blood-based biomarkers and early diagnosis of Alzheimer's disease","authors":["Cui Z","Li G","Wei S","Cheng Q","Yu Q","Zong S","Zhang P","Chen H","Yu S","Wu S","Li M","Lu Z"],"author_count":12,"year":2026,"published":"2026-01-27","venue":"Neural regeneration research","cited_by":0,"doi":"10.4103/nrr.nrr-d-25-00759","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.4103/nrr.nrr-d-25-00759","archive_url":"https://space-kitty.com/papers/doi:10.4103/nrr.nrr-d-25-00759","updated":null,"pmid":"41622474","pmcid":"PMC13568666","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC13568666/pdf","abstract":"Alzheimer's disease is a common neurodegenerative disease characterized by progressive memory loss, cognitive decline, and behavioral changes. Blood-based biomarkers have recently gained significant attention due to their accessibility and cost-effectiveness. This review highlights the latest progress in multiple key areas of blood-based biomarkers for Alzheimer's disease. For early diagnosis, blood-based biomarkers such as amyloid-β and phosphorylated tau can identify Alzheimer's disease even before clinical symptoms emerge. Dynamic changes in blood-based biomarkers, including p-tau217 and neurofilament light chain, reflect disease progression and correlate with cognitive decline, enabling continuous monitoring of Alzheimer's disease progression. Additionally, blood-based biomarkers such as p-tau181 and glial fibrillary acidic protein aid in differential diagnosis by distinguishing Alzheimer's disease from other dementias such as frontotemporal dementia. Blood-based biomarkers related to nerve repair have opened up new avenues for tracking nerve regeneration and therapeutic response, especially brain-derived neurotrophic factor. Furthermore, advanced detection technologies such as single-molecule array and immunoprecipitation-mass spectrometry have significantly improved the sensitivity and specificity of blood-based biomarkers, facilitating their clinical translation. In summary, blood-based biomarkers hold strong potential to improve early diagnosis, monitor progression, differential diagnosis, and evaluate therapies in Alzheimer's disease. This review provides a comprehensive and updated evaluation of the translational potential of blood-based biomarkers, emphasizing their practical utility in clinical settings and offering insights into future directions for large-scale application. This review emphasizes the need to prioritize the allocation of scientific resources, expedite the transition of blood-based biomarkers to clinical implementation, and ultimately achieve precise treatment of Alzheimer's disease using these biomarkers.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Blood-based biomarkers and early diagnosis of Alzheimer's disease\" by Cui Z, Li G, Wei S et al., https://doi.org/10.4103/nrr.nrr-d-25-00759, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}